



Value assessment for orphan drugs in Switzerland and the EU

31 October 2018
Basel Switzerland

Advanced Program

31 October 2018, Basel, Hotel Victoria, Centralbahnplatz 3–4, 4002 Basel

Registration: RDA-forum.org

Moderation: Daniel Dröschel, SFL

09.30 – 10.00	Registration & welcome coffee
10.00 – 10.10	Welcome and introduction
	Shayesteh Fürst-Ladani Rare Disease Action Forum, President
10.10 – 11.20	Switzerland
	Daniel Dröschel SFL, Senior Manager Market Access Ivo Hutzli Swiss Society for Cystic Fibrosis, Co-President
11.20 – 11.45	European overview
	Vinciane Pirard Sanofi Genzyme, Senior Director Public Affairs; Co-Chair Joint Task Force on Orphan Drugs & Rare Diseases of EFPIA – EuropaBio
11.45 – 12.30	Austria
	Dr. Anna Bucsics Mechanism of coordinated Access to Orphan Medicinal Products (MoCA), project advisor; Formerly, Head of Department of Pharmaceutical Affairs, Federation of Austrian Social Security Institutions
	Dr. Wolfgang Schnitzel Shire, General Manager Austria; Chair Pharmig (Austrian Association of the Pharmaceutical Industry) working group rare diseases
12.30 – 13.45	Lunch
13.45 – 15.15	Germany
	Johannes Morche The Federal Joint Committee (G-BA) Germany, Fachberatung Medizin
	Dr. Alexander Natz European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Secretary General
	Dr. Jasmin Barman-Aksözen International Porphyria Patient Network, Vice-President
15.15 – 15.35	Coffee break
15.35 – 16.00	France
	Dr. Thierry Marquet Shire, Head of Value Demonstration & Access France & Benelux
16.00 – 16.15	Wrap up
	Niklaus Wagner RDAF
16.30	End of program